The Financial Burden of Patient Comorbidities on Total Hip Arthroplasties—A Matched Cohort Analysis of High Comorbidity Burden and Non–High Comorbidity Burden Patients.

The impact of increased patient comorbidities on the cost-effectiveness of total hip arthroplasty (THAs) is lacking. This study aimed to compare revenue, costs, and short-term (90 days) surgical outcomes between patients who have and do not have a high comorbidity burden (HCB). We retrospectively reviewed 14,949 patients who underwent an elective, unilateral THA between 2012 and 2021. Patients were stratified into HCB (Charlson Comorbidity Index ≥ 5 and American Society of Anesthesiology scores of 3 or 4) and non-HCB groups, and were further 1:1 propensity matched based on baseline characteristics. Perioperative data, revenue, costs, and contribution margins (CMs) of the inpatient episode were compared between groups. Also, 90-day readmissions and revisions were compared between groups. Of the 11,717 patients who had available financial data (n = 1,017 HCB, n = 10,700 non-HCB), 1,914 patients were included in the final matched analyses (957 per group). Total (P <.001) and direct (P <.001) costs were significantly higher for HCB patients. Comparable revenue between cohorts (P =.083) resulted in a significantly decreased CM in the HCB patient group (P <.001). The HCB patients were less likely to be discharged home (P <.001) and had significantly higher 90-day readmission rates (P =.049). Increased THA costs for HCB patients were not matched by increased revenue, resulting in decreased CM. Higher rates of nonhome discharge and readmissions in the HCB population add to the additional financial burden. Adjustments to the current reimbursement models should better account for the increased financial burden of HCB patients undergoing THA and ensure access to care for all patient populations. III. [ABSTRACT FROM AUTHOR]